Brooks Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹109.85
- Today's High:
- ₹114
- Open Price:
- ₹114
- 52W Low:
- ₹57.05
- 52W High:
- ₹136.25
- Prev. Close:
- ₹112.1
- Volume:
- 103726
Company Statistics
- Market Cap.:
- ₹2.67 billion
- Book Value:
- 34.925
- Revenue TTM:
- ₹617.84 million
- Operating Margin TTM:
- -37.68%
- Gross Profit TTM:
- ₹128.06 million
- Profit Margin:
- -29.89%
- Return on Assets TTM:
- -13.68%
- Return on Equity TTM:
- -29.82%
Company Profile
Brooks Laboratories Limited had its IPO on under the ticker symbol BROOKS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Brooks Laboratories Limited has a staff strength of 296 employees.
Stock update
Shares of Brooks Laboratories Limited opened at ₹114 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹109.85 - ₹114, and closed at ₹109.85.
This is a -2.01% slip from the previous day's closing price.
A total volume of 103,726 shares were traded at the close of the day’s session.
In the last one week, shares of Brooks Laboratories Limited have increased by +8.07%.
Brooks Laboratories Limited's Key Ratios
Brooks Laboratories Limited has a market cap of ₹2.67 billion, indicating a price to book ratio of 4.6094 and a price to sales ratio of 3.3983.
In the last 12-months Brooks Laboratories Limited’s revenue was ₹617.84 million with a gross profit of ₹128.06 million and an EBITDA of ₹-162629504. The EBITDA ratio measures Brooks Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Brooks Laboratories Limited’s operating margin was -37.68% while its return on assets stood at -13.68% with a return of equity of -29.82%.
In Q2, Brooks Laboratories Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 8.3%.
Brooks Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-12.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Brooks Laboratories Limited’s profitability.
Brooks Laboratories Limited stock is trading at a EV to sales ratio of 3.8377 and a EV to EBITDA ratio of -11.4443. Its price to sales ratio in the trailing 12-months stood at 3.3983.
Brooks Laboratories Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.10 billion
- Total Liabilities
- ₹330.21 million
- Operating Cash Flow
- ₹4.95 million
- Capital Expenditure
- ₹4.68 million
- Dividend Payout Ratio
- 0%
Brooks Laboratories Limited ended 2024 with ₹1.10 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.10 billion while shareholder equity stood at ₹739.53 million.
Brooks Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹330.21 million in other current liabilities, 247028000.00 in common stock, ₹492.51 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹10.52 million and cash and short-term investments were ₹13.78 million. The company’s total short-term debt was ₹56,635,000 while long-term debt stood at ₹0.00.
Brooks Laboratories Limited’s total current assets stands at ₹276.06 million while long-term investments were ₹0 and short-term investments were ₹3.03 million. Its net receivables were ₹127.54 million compared to accounts payable of ₹233.70 million and inventory worth ₹113.03 million.
In 2024, Brooks Laboratories Limited's operating cash flow was ₹4.95 million while its capital expenditure stood at ₹4.68 million.
Comparatively, Brooks Laboratories Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹109.85
- 52-Week High
- ₹136.25
- 52-Week Low
- ₹57.05
- Analyst Target Price
- ₹
Brooks Laboratories Limited stock is currently trading at ₹109.85 per share. It touched a 52-week high of ₹136.25 and a 52-week low of ₹136.25. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹92.32 and 200-day moving average was ₹87.25 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6751.2% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Brooks Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. It offers liquid and dry powder injection, carbapenem drugs, tablets, dry syrup, and eye/ear drops. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.